Nitrogen-containing heterocyclic ketones, their preparation methods and pharmaceutical uses

By providing selective cardiac sarcoma modulatory compounds, the problem of existing drugs being unable to inhibit the progression of HCM has been solved, achieving effective treatment for ventricular hypertrophy and cardiomyocyte disorders, and reducing the risk of death for patients.

CN117460717BActive Publication Date: 2026-11-17JIANGSU HENGRUI MEDICINE CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202280020982.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2021-12-06
Filing Date
2022-03-17
Publication Date
2026-11-17
Estimated Expiration
2042-03-17

AI Technical Summary

Technical Problem

Existing drugs for treating hypertrophic cardiomyopathy (HCM) are ineffective in inhibiting the progression of ventricular hypertrophy, cardiomyocyte disorder, and myocardial fibrosis, and there is a lack of selective cardiac sarcomere modulators to improve symptoms and reduce mortality.

Method used

Selective cardiac sarcomere modulators, such as cardiac myosin inhibitors, are provided for the treatment of HCM via compound of formula (I) and its pharmaceutically acceptable salts, solvates, or prodrugs, including their tautomers, isomers, and mixtures.

Benefits of technology

It effectively treats HCM, inhibits ventricular hypertrophy and cardiomyocyte disorder, improves cardiac function, and reduces patient mortality.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure QLYQS_1
    Figure QLYQS_1
  • Figure QLYQS_2
    Figure QLYQS_2
  • Figure QLYQS_3
    Figure QLYQS_3
Patent Text Reader

Abstract

This invention provides novel N-heterocyclic ketones for the treatment of hypertrophic cardiomyopathy (HCM) and other heart diseases. Methods for their preparation, pharmaceutical compositions comprising said compounds, and pharmaceutical uses for the treatment of HCM and other forms of heart disease or conditions are also disclosed.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the pharmaceutical field and relates to nitrogen-containing heterocyclic ketones, their preparation methods, pharmaceutical compositions containing such compounds, and their pharmaceutical uses. Background Technology

[0002] Hypertrophic cardiomyopathy (HCM) is a hereditary disease with an incidence of approximately 1 in 500 in the general population. Patients with HCM are frequently diagnosed with left ventricular hypertrophy that cannot be explained by other known causes. Other significant histopathological findings in HCM include enlarged, disorganized cardiomyocytes and increased myocardial fibrosis. Cardiac function in patients with HCM is also impaired due to characteristic hyperdynamic impaired contraction and relaxation.

[0003] Patients with underlying familial or somatic mutations in hemocardiosis (HCM) may experience symptoms including chest pain, shortness of breath, fatigue, palpitations, and even sudden death. Despite its prevalence and severe symptoms, targeted therapies available to improve HCM at its source and alter its progression are scarce. Currently used off-label medications, such as beta-adrenergic receptor blockers or calcium channel blockers, can nonspecifically reduce myocardial contractility, thus alleviating some symptoms, but these treatments do not alter disease progression. There is a strong need for agents that can inhibit the progression of ventricular hypertrophy, cardiomyocyte disorder, and myocardial fibrosis.

[0004] Selective inhibition of hyperconstrictivity of cardiac sarcomeres is a promising targeting approach for hemolytic muscular dystrophy (HCM). Novel mechanisms of action can offer therapeutic advantages in symptom relief, improved therapeutic window, and reduced patient mortality. Therefore, there is a need in the art for novel selective cardiac sarcomere modulators. Summary of the Invention

[0005] Selective cardiac sarcomere modulators, such as cardiac myosin inhibitors, have been identified as effective agents for the treatment of HCM in preclinical and clinical settings. This disclosure provides for such agents and methods of use thereof.

[0006] In one general aspect, the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt, solvate, or prodrug thereof, comprising tautomers, cis or trans isomers, meso compounds, racemates, enantiomers, diastereomers, and mixtures thereof:

[0007]

[0008] in:

[0009] A is selected from:

[0010]

[0011] R is -CR1R2)n R3;

[0012] R1 and R2 are independently selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, alkyl, alkoxy, haloalkyl, hydroxyalkyl, cycloalkyl, heterocyclic, aryl, and heteroaryl.

[0013] n can be 0, 1, 2, 3, or 4;

[0014] R3 is selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, alkyl, alkoxy, haloalkyl, hydroxyalkyl, cycloalkyl, heterocyclic, aryl, and heteroaryl, wherein each of the alkyl, alkoxy, haloalkyl, hydroxyalkyl, cycloalkyl, heterocyclic, aryl, and heteroaryl groups is independently unsubstituted or substituted by one or more groups selected from R3 in each occurrence. 3 Substituent substitution of the group, wherein R 3 The functional groups include deuterium, halogen, amino, nitro, oxo, cyano, hydroxyl, alkyl, alkoxy, haloalkyl, hydroxyalkyl, and -NR. a R b -C(O)R a -C(O)NR a R b -C(O)OR a -OC(O)R a -S(O) m R a -S(O) m NR a R b Composed of cycloalkyl, heterocyclic, aryl, and heteroaryl groups, wherein the R substituents are... 3 The alkyl, hydroxyalkyl, cycloalkyl, heterocyclic, aryl, and heteroaryl groups in the group are independently unsubstituted or replaced by one or more groups selected from alkyl, haloalkyl, cyano, -C(O)R a Substitution with halogens and cycloalkyl groups;

[0015] m is 0, 1, or 2;

[0016] R' is selected from alkyl, alkoxy, haloalkyl, hydroxyalkyl, cycloalkyl, heterocyclic, aryl, and heteroaryl, wherein each of the alkyl, alkoxy, haloalkyl, hydroxyalkyl, cycloalkyl, heterocyclic, aryl, and heteroaryl groups is independently unsubstituted or substituted by one or more groups selected from deuterium, halogen, amino, cyano, hydroxy, alkyl, alkoxy, haloalkyl, hydroxyalkyl, -NR c R d -C(O)R c -C(O)NR c R d -C(O)OR c -OC(O)R c -S(O)m R c and -S(O) m NR c R d Substituents of the substituents;

[0017] R a R b R c and R d It is independently selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, alkyl, alkoxy, haloalkyl and hydroxyalkyl.

[0018] In one embodiment, the compound of formula (I) is a compound of formula (II), or a tautomer, cis or trans isomer, meso compound, racemic compound, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof.

[0019]

[0020] in,

[0021] R1 is selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C3-C8 cycloalkyl, 4-8 membered heterocyclic, C6-C 12 Aryl and 4-8 membered heteroaryl;

[0022] R3 is selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C3-C8 cycloalkyl, 4-8 membered heterocyclic groups containing one or more N, O, S and S(O)2, C6-C 12 aryl and 4-8 membered heteroaryl groups comprising one or more N, O, S and S(O)2, wherein C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C3-C8 cycloalkyl, 4-8 membered heterocyclic, C6-C 12 Each of the aryl and 4-8 heteroaryl groups is independently unsubstituted or substituted with one or more components selected from R each time it appears. 3 Substituent substitution of the group, wherein R 3 The functional groups include deuterium, halogen, amino, nitro, oxo, cyano, hydroxyl, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, and -NR. a R b -C(O)R a -C(O)NR a R b -C(O)OR a -OC(O)Ra -S(O) m R a and -S(O) m NR a R b Composition, wherein the substituent of the R 3 The C3-C6 cycloalkyl group, 4-6 membered heterocyclic group containing one or more N, O, S and S(O)2, phenyl group, 4-6 membered heteroaryl group containing one or more N, O, S and S(O)2, C1-C6 alkyl group and C1-C6 hydroxyalkyl group are independently unsubstituted or substituted by one or more groups selected from C1-C6 alkyl group, C1-C6 haloalkyl group, cyano group, -C(O)R group. a Substitution with halogens and C3-C6 cycloalkyl groups;

[0023] R4 and R5 are independently selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C3-C8 cycloalkyl, 4-8 membered heterocyclic groups containing one or more N, O, S and S(O)2, C6-C 12 aryl and 4-8 membered heteroaryl groups comprising one or more N, O, S and S(O)2, wherein C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C3-C8 cycloalkyl, 4-8 membered heterocyclic, C6-C 12 Each of the aryl and 4-8 heteroaryl groups is independently unsubstituted or replaced by one or more groups selected from deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, -NR c R d -C(O)R c -C(O)NR c R d -C(O)OR c and -OC(O)R c Substituents of the substituents;

[0024] Alternatively, R4 and R5, together with the C atoms they are bonded to, form a mixture selected from R... 45 The cyclic structure of the Cycle group, wherein R 45 The Cycle group consists of C3-C8 cycloalkyl groups, 4-8 membered heterocyclic groups containing one or more N and O atoms, and C6-C... 12 It consists of an aryl group and a 4-8 membered heteroaryl group containing one or more N and O, wherein the R 45Each of the ring structures in the Cycle group is optionally surrounded by one to four elements selected from deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 hydroxyalkyl, -NR c R d -C(O)R c -C(O)NR c R d -C(O)OR c and -OC(O)R c Substituents of the substituents;

[0025] R a R b R c and R d It is independently selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl and C1-C6 hydroxyalkyl.

[0026] In some implementations, R4 and R5, together with the C atoms to which they are bonded, form 4-8 membered heterocyclic groups containing N atoms.

[0027] In some embodiments, R1 is selected from hydrogen, hydroxyl, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, and C1-C3 hydroxyalkyl.

[0028] In some implementations, R1 is H, -OH, –CH3, –CH2CH3, –CH(CH3)2, –CH2OH, -CF3, or

[0029] In some embodiments, R3 is selected from C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 hydroxyalkyl, C3-C6 cycloalkyl, phenyl, 5-6 membered heterocyclic groups comprising 1-2 N, O, S and S(O)2 and 5-6 membered heteroaryl groups comprising 1-2 N, O, S and S(O)2, wherein each of the substituents in R3 is optionally replaced by one or two substituents selected from R 3 Substituent substitution of the group, wherein R 3 The functional groups include deuterium, halogen, amino, nitro, oxo, cyano, hydroxyl, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 haloalkyl, C1-C3 hydroxyalkyl, 4-6 membered heterocyclic groups containing one or more N, O, S and S(O)2, and -C(O)R. a -C(O)NR a R b -S(O)2R a and -S(O)2NR a R bComposition, wherein the R in the substituent 3 The C1-C3 alkyl, C1-C3 hydroxyalkyl, and 4-6 membered heterocyclic groups containing one or more N, O, S, and S(O)2 groups are independently unsubstituted or replaced by one or more groups selected from C1-C3 alkyl, C1-C3 haloalkyl, cyano, -C(O)R a Substitution with halogens and C3-C6 cycloalkyl groups.

[0030] In some implementation schemes, R a and R b It is independently selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 haloalkyl and C1-C3 hydroxyalkyl.

[0031] In some embodiments, R4 and R5 are independently selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 haloalkyl, C1-C3 hydroxyalkyl, C3-C6 cycloalkyl, 5-6 membered heterocyclic groups containing 1-2 N, O, S and S(O)2, C6-C 12 Aryl groups and 5-6 heteroaryl groups comprising 1-2 N, O, S, and S(O)2, wherein C1-C3 alkyl, C1-C3 alkoxy, C1-C3 haloalkyl, C1-C3 hydroxyalkyl, C3-C6 cycloalkyl, 5-6 heterocyclic, C6-C 12 Each of the aryl and 5-6 heteroaryl groups is independently unsubstituted or substituted with one or more groups selected from deuterium, halogen, amino, cyano, hydroxyl, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 haloalkyl, C1-C3 hydroxyalkyl, -NR c R d -C(O)R c -C(O)NR c R d -C(O)OR c and -OC(O)R c Substituents are substituted.

[0032] In some implementations, R4 and R5, together with the C atoms they are bonded to, form a group selected from C. 45 The cyclic structure of the Cycle(II) group, wherein the C 45 The Cycle(II) group is composed of a C3-C6 cycloalkyl group, a 5-6 membered heterocyclic group containing 1-2 N and O atoms, a phenyl group, and a 5-6 membered heteroaryl group containing 1-2 N and O atoms, wherein the C 45Each of the ring structures in the Cycle(II) group is optionally composed of one or two elements selected from deuterium, halogen, amino, cyano, hydroxyl, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 hydroxyalkyl, -NR c R d -C(O)R c -C(O)NR c R d -C(O)OR c and -OC(O)R c Substituents are substituted.

[0033] In some implementation schemes, R c and R d It is independently selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 haloalkyl and C1-C3 hydroxyalkyl.

[0034] In some implementations, R4 and R5 are independently selected from -CH3 and -CF3.

[0035] In some implementations, R4 and R5 are -CH3.

[0036] In some embodiments, R4 and R5, together with the C atoms they are bonded to, form a ring structure selected from RCycle groups, which consist of the following:

[0037] Each of the ring structures in the RCycle group is optionally substituted by one or two substituents selected from –F, -Cl, -Br, -OH, -CH3, -CH2CH3, –CF3 and -C(O)CH3.

[0038] In some implementations, n is 0, 1, or 2.

[0039] In some implementations, n is 1.

[0040] In some embodiments, the compound of formula (II) is a compound of formula (III), or a tautomer, cis or trans isomer, meso compound, racemic compound, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof.

[0041]

[0042] R1, R3, R4 and R5 are defined as in equation (II).

[0043] In some implementations, n is 0 when each of R4 and R5 is methyl, and R3 is neither methyl nor methyl. Not for

[0044] In some implementations, n is 1 when each of R1, R4, and R5 is methyl, and R3 is not methyl.

[0045] In some implementations, when R4 and R5 are formed together with the C atoms they are bonded to... When R1 is a methyl group, then n is 1, and R3 is not.

[0046] In some embodiments, the compound of formula (III) is a compound of formula (IV), or a tautomer, cis or trans isomer, meso compound, racemic compound, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof.

[0047]

[0048] in,

[0049] R1 is a C1-C3 alkyl, C1-C3 haloalkyl, or C1-C3 alkoxy;

[0050] R4 and R5, together with the C atoms they are bonded to, form 5-6 membered heterocyclic groups containing 1-2 N and O atoms; and

[0051] R6 is independently selected from halogens, C1-C3 alkyl groups, C1-C3 alkoxy groups, and C1-C3 haloalkyl groups.

[0052] In some embodiments of a compound of formula (IV), or a tautomer, cis or trans isomer, meso compound, racemic compound, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof:

[0053] R1 is a C1-C3 alkyl group;

[0054] R4 and R5, together with the C atoms they are bonded to, form and

[0055] R6 is independently selected from F, Cl, and Br.

[0056] The present invention also provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of any of the forms described herein, or a tautomer, cis or trans isomer, meso compound, racemic compound, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, and one or more pharmaceutically acceptable carriers, diluents, or excipients.

[0057] In another aspect, the present invention relates to a method for treating hypertrophic cardiomyopathy (HCM) or heart disease with HCM pathophysiological features in a subject of need, the method comprising administering to the subject an effective amount of a compound of any of the forms described herein or a pharmaceutical composition comprising therethe.

[0058] In a preferred embodiment, the HCM is obstructive or non-obstructive, or caused by sarcomere and / or non-sarcomere mutations.

[0059] In another aspect, the present invention relates to a method for treating a disease or condition selected from heart failure with normal ejection fraction, ischemic heart disease, angina pectoris, and restrictive cardiomyopathy, the method comprising administering to a subject in need an effective amount of a compound of any of the forms described herein or a pharmaceutical composition comprising therethe. Attached Figure Description

[0060] Figure 1 The effects of the compound of Example 4 on cardiac function were measured in Spraw-Dawley rats at different doses.

[0061] Figure 2 The effects of the compound of Example 10 on cardiac function were measured in Spraw-Dawley rats at different doses. Detailed Implementation

[0062] Various publications, articles, and patents are referenced or described throughout this specification; each of these references is incorporated herein by reference in its entirety. Discussions of the documents, actions, materials, devices, articles, etc., included in this specification are for the purpose of providing context for this disclosure. Such discussions do not imply that any or all of these matters constitute part of the prior art relating to this disclosure.

[0063] The following are definitions of the terms used in this invention. Any term not defined herein shall have the ordinary meaning as understood by those skilled in the art.

[0064] In cases where a group or substituent is declared to be "independently selected" from (and its variants) the list of options, this means that the selection of any one of these groups or substituents does not determine the selection of any other one of these groups or substituents. For illustrative purposes, but not as a limitation, the terms "A and B are independently selected from a and b" or "each of A and B is independently selected from a and b" are intended to cover the selections of A being a and B being a, A being b and B being b, A being a and B being b, and A being b and B being a.

[0065] It should be noted that, as used herein and in the appended claims, the singular forms “a,” “an,” and “the” include plural references unless the context clearly specifies otherwise.

[0066] Unless otherwise stated, the term "at least" preceding a series of elements should be understood to mean each element in the series. For example, the phrase "at least A, B, and C" means that each of A, B, and C is present. The term "at least one" preceding a series of elements should be understood to mean a single element in the series or any combination of two or more elements in the series. For example, the phrase "at least one of A, B, and C" means that only A is present, only B is present, only C is present, both A and B are present, both A and C are present, both B and C are present, or each of A, B, and C is present. Depending on the context, "at least one" preceding a series of elements can also cover the situation where any one or more of the three elements are present in more than one case; for example, "at least one of A, B, and C" can also cover the situation where A is present alone or further present in combination with any one or more of elements B and C.

[0067] As used herein, the connecting term "and / or" between multiple listed elements is understood to encompass both individual and combined options. For example, in the case of two elements connected by "and / or", the first option is that the first element exists while the second element does not. The second option is that the second element exists while the first element does not. The third option is that both the first and second elements exist. Any of these options is understood to fall within this meaning and thus satisfy the requirement of the term "and / or" as used herein. The simultaneous existence of multiple options is also understood to fall within this meaning and thus satisfy the requirement of the term "and / or".

[0068] "Alkyl" refers to a saturated aliphatic hydrocarbon group, including C1-C64 groups. 20Straight-chain and branched-chain groups. Preferably, the alkyl group is an alkyl group having 1 to 12, sometimes more preferably 1 to 6, and sometimes more preferably 1 to 4 carbon atoms. Representative examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl 2,3-Dimethylpentyl, 2,4-Dimethylpentyl, 2,2-Dimethylpentyl, 3,3-Dimethylpentyl, 2-Ethylpentyl, 3-Ethylpentyl, n-Octyl, 2,3-Dimethylhexyl, 2,4-Dimethylhexyl, 2,5-Dimethylhexyl, 2,2-Dimethylhexyl, 3,3-Dimethylhexyl, 4,4-Dimethylhexyl, 2-Ethylhexyl, 3-Ethylhexyl, 4-Ethylhexyl, 2-Methyl-2-Ethylpentyl, 2-Methyl-3-Ethylpentyl, n-Nonyl, 2-Methyl-2-Ethylhexyl, 2-Methyl-3-Ethylhexyl, 2,2-Diethylpentyl, n-Decyl, 3,3-Diethylhexyl, 2,2-Diethylhexyl, and their branched isomers. More preferably, the alkyl group is a lower alkyl group having 1 to 6 carbon atoms. Representative examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, etc. The alkyl group can be substituted or unsubstituted. When substituted, the substituent can be substituted at any available connection point. Preferably, the substituent is one or more substituents independently selected from alkyl, halogen, alkoxy, alkenyl, alkynyl thio, alkylamino, mercapto, hydroxyl, nitro, cyano, amino, cycloalkyl, heterocyclic, aryl, heteroaryl, cycloalkoxy, heterocyclic, cycloalkyl thio, heterocyclic, and oxo.

[0069] "Alkenyl" refers to an alkyl group as defined above that has at least two carbon atoms and at least one carbon-carbon double bond, such as vinyl, 1-propenyl, 2-propenyl, 1-, 2-, or 3-butenyl, preferably C10. 2-20 alkenyl, more preferably C2-12 Alkenyl group, C is the most preferred. 2-6 Alkenyl. The alkenyl group can be substituted or unsubstituted. When substituted, the substituent is preferably one or more, sometimes preferably one to five, and sometimes more preferably one to three groups independently selected from alkyl, halogen, alkoxy, alkenyl, alkynyl thio, alkylamino, mercapto, hydroxyl, nitro, cyano, amino, cycloalkyl, heterocyclic, aryl, heteroaryl, cycloalkoxy, heterocyclic, cycloalkylthio, heterocyclic, and oxo.

[0070] "Alkynyl" refers to an alkyl group as defined above that has at least two carbon atoms and at least one carbon-carbon triple bond, such as ethynyl, 1-propynyl, 2-propynyl, 1-, 2-, or 3-butynyl, preferably C10. 2-20 Alkyne group, more preferably C 2-12 Alkyne group, C is the preferred group 2-6 Alkynyl. The alkynyl group can be substituted or unsubstituted. When substituted, the substituent is preferably one or more, sometimes preferably one to five, and sometimes more preferably one to three groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocyclic, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, and heterocycloalkylthio.

[0071] "Alkylene" refers to a saturated straight-chain or branched aliphatic hydrocarbon group having two residues derived by removing two hydrogen atoms from the same carbon atom or two different carbon atoms of a parent alkane. Straight-chain or branched groups containing 1 to 20 carbon atoms preferably have 1 to 12 carbon atoms, more preferably 1 to 6 carbon atoms. Non-limiting examples of alkylene include, but are not limited to, methylene (-CH2-), 1,1-ethylene (-CH(CH3)-), 1,2-ethylene (-CH2CH2)-), 1,1-propylene (-CH(CH2CH3)-), 1,2-propylene (-CH2CH(CH3)-), 1,3-propylene (-CH2CH2CH2-), 1,4-butylene (-CH2CH2CH2CH2-), etc. Alkylenes can be substituted or unsubstituted. When substituted, the substituents are preferably one or more, sometimes preferably one to five, and sometimes more preferably one to three groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocyclic, aryl, heteroaryl, cycloalkoxy, heterocyclic alkoxy, cycloalkylthio, and heterocyclic alkylthio.

[0072] "Alkenylene" refers to an alkylene group as defined above, having at least two carbon atoms and at least one carbon-carbon double bond, preferably C. 2-20 alkenyl, more preferably C 2-12 alkenyl groups, with C being the most preferred. 2-6Alkenyl group. Non-limiting examples of alkenyl groups include, but are not limited to, -CH=CH-, -CH=CHCH2-, -CH=CHCH2CH2-, -CH2CH=CHCH2-, etc. Alkenyl groups can be substituted or unsubstituted. When substituted, the substituents are preferably one or more, sometimes preferably one to five, and sometimes more preferably one to three groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocyclic, aryl, heteroaryl, cycloalkoxy, heterocyclic alkoxy, cycloalkylthio, and heterocyclic alkylthio.

[0073] "Immyneyl" refers to an ynyl group as defined above, having at least two carbon atoms and at least one carbon-carbon triple bond, preferably C. 2-20 Ethyne group, more preferably C 2-12 alkyne group, C is the preferred group 2-6 Alynyl group. Non-limiting examples of alynyl groups include, but are not limited to, -CH≡CH-, -CH≡CHCH2-, -CH≡CHCH2CH2-, -CH2CH≡CHCH2-, etc. Alynyl groups can be substituted or unsubstituted. When substituted, the substituents are preferably one or more, sometimes preferably one to five, and sometimes more preferably one to three groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocyclic, aryl, heteroaryl, cycloalkoxy, heterocyclic alkoxy, cycloalkylthio, and heterocyclic alkylthio groups.

[0074] "Cycloalkyl" refers to a saturated and / or partially unsaturated monocyclic or polycyclic hydrocarbon group having 3 to 20 carbon atoms, preferably 3 to 12 carbon atoms, more preferably 3 to 10 carbon atoms, and most preferably 3 to 8 carbon atoms or 3 to 6 carbon atoms. Representative examples of monocyclic cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cyclohepttrienyl, and cyclooctyl. Polycyclic cycloalkyl groups include cycloalkyl groups having spirocyclic, fused, or bridged rings.

[0075] "Spirocycloalkyl" refers to a 5- to 20-membered polycyclic group, wherein the rings are linked by a common carbon atom (called a spiro atom), and one or more rings may contain one or more double bonds, but none of the rings have a fully conjugated π-electron system. Preferably, the spirocycloalkyl group is 6- to 14-membered, more preferably 7- to 10-membered. Based on the common number of spiro atoms, spirocycloalkyl groups are classified as monospirocycloalkyl, dispirocycloalkyl, or polyspirocycloalkyl, preferably monospirocycloalkyl or dispirocycloalkyl, more preferably 4-membered / 4-membered, 4-membered / 5-membered, 4-membered / 6-membered, 5-membered / 5-membered, or 5-membered / 6-membered monospirocycloalkyl. Representative examples of spirocycloalkyl groups include, but are not limited to, the following substituents:

[0076]

[0077] "Fused cycloalkyl" refers to a 5- to 20-membered polycyclic hydrocarbon group, wherein each ring in the system shares an adjacent pair of carbon atoms with another ring, and one or more rings may contain one or more double bonds, but none of the rings has a fully conjugated π-electron system. Preferably, the fused cycloalkyl is 6- to 14-membered, more preferably 7- to 10-membered. Based on the number of member rings, fused cycloalkyl is classified into bicyclic, tricyclic, tetracyclic, or polycyclic fused cycloalkyl, preferably bicyclic or tricyclic fused cycloalkyl, more preferably 5-membered / 5-membered or 5-membered / 6-membered bicyclic fused cycloalkyl. Representative examples of fused cycloalkyl include, but are not limited to, the following substituents:

[0078]

[0079] "Bridged cycloalkyl" refers to a 5- to 20-membered polycyclic hydrocarbon group, wherein each pair of rings shares two unconnected carbon atoms. The rings may have one or more double bonds, but do not have a fully conjugated π-electron system. Preferably, the bridged cycloalkyl group is 6- to 14-membered, more preferably 7- to 10-membered. Based on the number of member rings, bridged cycloalkyl groups are classified as bicyclic, tricyclic, tetracyclic, or polycyclic bridged cycloalkyl groups, preferably bicyclic, tricyclic, or tetracyclic bridged cycloalkyl groups, more preferably bicyclic or tricyclic bridged cycloalkyl groups. Representative examples of bridged cycloalkyl groups include, but are not limited to, the following substituents:

[0080]

[0081] Cycloalkyl groups can be fused with aryl, heteroaryl, or heterocyclic rings, wherein the ring bonded to the parent structure is a cycloalkyl group. Representative examples include, but are not limited to, indanylacetic acid, tetrahydronaphthalene, and benzocycloheptanyl.

[0082]

[0083] The cycloalkyl group may be optionally substituted or unsubstituted. When substituted, the substituents are preferably one or more, sometimes preferably one to five, and sometimes more preferably one to three substituents independently selected from alkyl, halogen, alkoxy, alkenyl, alkynyl, alkylthio, alkylamino, mercapto, hydroxyl, nitro, cyano, amino, cycloalkyl, heterocyclic, aryl, heteroaryl, cycloalkoxy, heterocyclic, cycloalkylthio, heterocyclic, and oxo.

[0084] "Heterocyclic group" refers to a 3- to 20-membered saturated and / or partially unsaturated monocyclic or polycyclic hydrocarbon group, having one or more, sometimes preferably one to five, and sometimes more preferably one to three selected from N, O, and S(O). mHeteroatoms (where m is 0, 1, or 2) are used as ring atoms, but the ring does not include -OO-, -OS-, or -SS-, and the remaining ring atoms are C. Preferably, the heterocyclic group is a 3- to 12-membered heterocyclic group having 1 to 4 heteroatoms; more preferably, a 3- to 10-membered heterocyclic group having 1 to 3 heteroatoms; and most preferably, a 5- to 6-membered heterocyclic group having 1 to 2 heteroatoms. Representative examples of monocyclic heterocyclic groups include, but are not limited to, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, and homopiperazinyl. Polycyclic heterocyclic groups include heterocyclic groups having spirocyclic, fused, or bridged rings.

[0085] "Spiroheterocyclic group" refers to a 5- to 20-membered polycyclic heterocyclic group, wherein the rings are connected by a common carbon atom (called a spiro atom), and wherein the rings have one or more, sometimes preferably one to five, and sometimes more preferably one to three selected from N, O, and S(O). m Heteroatoms (where m is 0, 1, or 2) are used as ring atoms, and the remaining ring atoms are carbon atoms. One or more rings may contain one or more double bonds, but none of the rings has a fully conjugated π-electron system. Preferably, the spiroheterocyclic group is 6 to 14 quinary, more preferably 7 to 10 quinary. Based on the common number of spiro atoms, spiroheterocyclic groups are classified into monospiroheterocyclic, dispiroheterocyclic, or polyspiroheterocyclic groups, preferably monospiroheterocyclic or dispiroheterocyclic, more preferably 4 / 4, 4 / 5, 4 / 6, 5 / 5, or 5 / 6 monospiroheterocyclic groups. Representative examples of spiroheterocyclic groups include, but are not limited to, the following substituents:

[0086]

[0087] "Fused heterocyclic group" refers to a 5- to 20-membered polycyclic heterocyclic group, wherein each ring in the system shares an adjacent pair of carbon atoms with the other rings, wherein one or more rings may contain one or more double bonds, but none of the rings has a fully conjugated π-electron system, wherein the rings have one or more, sometimes preferably one to five, and sometimes more preferably one to three selected from N, O, and S(O). p Heteroatoms (where p is 0, 1, or 2) are used as ring atoms, and the remaining ring atoms are carbon. Preferably, the fused heterocyclic group is 6 to 14 members, more preferably 7 to 10 members. Depending on the number of member rings, fused heterocyclic groups are classified into bicyclic, tricyclic, tetracyclic, or polycyclic fused heterocyclic groups, preferably bicyclic or tricyclic fused heterocyclic groups, more preferably 5-membered / 5-membered or 5-membered / 6-membered bicyclic fused heterocyclic groups. Representative examples of fused heterocyclic groups include, but are not limited to, the following substituents:

[0088]

[0089]

[0090] "Bridged heterocyclic group" refers to a 5- to 14-membered polycyclic heterocyclic group in which every two rings share two unconnected atoms. The rings may have one or more double bonds, but do not have a fully conjugated π-electron system. The rings have one or more atoms selected from N, O, and S(O). m (Where m is 0, 1, or 2) heteroatoms are used as ring atoms, and the remaining ring atoms are carbon. Preferably, the bridging heterocyclic group is 6 to 14 members, more preferably 7 to 10 members. Based on the number of member rings, bridging heterocyclic groups are classified into bicyclic, tricyclic, tetracyclic, or polycyclic bridging heterocyclic groups, preferably bicyclic, tricyclic, or tetracyclic bridging heterocyclic groups, more preferably bicyclic or tricyclic bridging heterocyclic groups. Representative examples of bridging heterocyclic groups include, but are not limited to, the following substituents:

[0091]

[0092] The ring of the heterocyclic group may be fused with the ring of an aryl, heteroaryl, or cycloalkyl group, wherein the ring bonded to the parent structure is a heterocyclic group. Representative examples include, but are not limited to, the following substituents:

[0093] wait.

[0094] The heterocyclic group may be optionally substituted or unsubstituted. When substituted, the substituent is preferably one or more, sometimes preferably one to five, and sometimes more preferably one to three, independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocyclic, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, and -NR. 9 R 10 . group.

[0095] "Aryl" refers to a 6- to 14-membered all-carbon monocyclic or polycyclic fused ring (a "fused" ring system is one in which each ring shares an adjacent pair of carbon atoms with another ring in the system) group, having a fully conjugated π-electron system. Preferably, the aryl group is 6- to 10-membered, such as phenyl and naphthyl, with phenyl being the most preferred. The aryl group can be fused with a heteroaryl, heterocyclic, or cycloalkyl ring, wherein the ring bonded to the parent structure is an aryl group. Representative examples include, but are not limited to, the following substituents:

[0096]

[0097] The aryl group can be substituted or unsubstituted. When substituted, the substituent is preferably one or more, sometimes preferably one to five, and sometimes more preferably one to three substituents independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocyclic, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, and heterocycloalkylthio.

[0098] "Heteroaryl" refers to an aryl system having 1 to 4 heteroatoms selected from O, S, and N as ring atoms and having 5 to 14 ring atoms. Preferably, the heteroaryl group is 5 to 10-membered, more preferably 5 or 6-membered, such as thiadiazolyl, pyrazolyl, oxazolyl, oxadiazolyl, imidazolyl, triazolyl, thiazolyl, furanyl, thiophene, pyridinyl, pyrroleyl, N-alkylpyrroleyl, pyrimidinyl, pyrazinyl, imidazolyl, tetrazolyl, etc. The heteroaryl group can be fused with the ring of an aryl, heterocyclic, or cycloalkyl group, wherein the ring bonded to the parent structure is a heteroaryl group. Representative examples include, but are not limited to, the following substituents:

[0099]

[0100] The heteroaryl group can be substituted or unsubstituted. When substituted, the substituent is preferably one or more, sometimes preferably one to five, and sometimes more preferably one to three substituents independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocyclic, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, and heterocycloalkylthio.

[0101] "Alkoxy" refers to -O- (alkyl) and -O- (unsubstituted cycloalkyl) groups, where the alkyl group is as defined above. Representative examples include, but are not limited to, methoxy, ethoxy, propoxy, butoxy, cyclopropoxy, cyclobutoxy, cyclopentoxy, and cyclohexoxy. Alkoxy groups can be substituted or unsubstituted. When substituted, the substituents are preferably one or more, sometimes preferably one to five, and sometimes more preferably one to three, independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocyclic, aryl, heteroaryl, cycloalkoxy, heterocyclic alkoxy, cycloalkylthio, and heterocyclic alkylthio.

[0102] A "bond" refers to a covalent bond that uses the "-" symbol.

[0103] "Hydroxyalkyl" refers to an alkyl group that has been replaced by a hydroxyl group, where the alkyl group is as defined above.

[0104] "Hydroxyl" or "hydroxyl" refers to the -OH group.

[0105] "Halogen" or "halogenated" refers to fluorine, chlorine, bromine, or iodine.

[0106] "Amino" refers to the -NH2 group.

[0107] "Cyano" refers to the -CN group.

[0108] "Nitro" refers to the -NO2 group.

[0109] "Oxide group" refers to the =O group.

[0110] "Carboxyl group" refers to the -C(O)OH group.

[0111] "Alkoxycarbonyl" refers to a -C(O)O (alkyl) or (cycloalkyl) group, where alkyl and cycloalkyl are as defined above.

[0112] "Optional" or "optionally" means that the event or environment described below may but does not have to occur, and the description includes the possibility or absence of such event or environment. For example, "optionally alkyl-substituted heterocyclic group" means that the alkyl group may but does not have to be present, and the description includes cases where the heterocyclic group is substituted with an alkyl group and cases where the heterocyclic group is not substituted with an alkyl group.

[0113] "Substituted" means that one or more hydrogen atoms in a group are independently replaced by a corresponding number of substituents. In some embodiments, the number of such hydrogen atoms is up to five. In other embodiments, it is one to three. It goes without saying that the substituents are only in their possible chemical positions. Those skilled in the art can determine (by experiment or theory) possible or impossible substitutions without much effort. For example, an amino or hydroxyl group with free hydrogen atoms may be unstable when bonded to a carbon atom with an unsaturated bond (such as an alkene).

[0114] "Pharmaceutical composition" refers to a mixture of one or more compounds described in this invention, or their physiologically / pharmaceutical acceptable salts or prodrugs, with other chemical components (such as physiologically / pharmaceutical acceptable carriers and excipients). The purpose of a pharmaceutical composition is to facilitate administration of the compound to a living organism, thereby promoting the absorption of the active ingredient and the exertion of its biological activity.

[0115] "Pharmaceutically acceptable salts" refers to salts of the compounds described herein that are safe and effective in mammals and possess the corresponding biological activity.

[0116] Those skilled in the art will recognize that, in some embodiments, the compounds described herein may have one or more asymmetric carbon atoms in their structure. As used herein, any chemical formula having bonds shown only as solid lines and not as solid wedges or scattered wedges considers every possible stereoisomer, or a mixture of two or more stereoisomers. Stereoisomers include enantiomers and diastereomers. Enantiomers are stereoisomers that are non-overlapping mirror images of each other. A 1:1 mixture of a pair of enantiomers is a racemic mixture or a racemic mixture. Diastereomers (or diastereomers) are stereoisomers that are not diastereomers, i.e., they are not mirror images of each other, and occur when two or more stereoisomers of a compound have different configurations at one or more equivalent stereocenters and are not mirror images of each other. Substituents (e.g., alkyl, heterocyclic, etc.) may contain stereocenters with R or S configurations.

[0117] Therefore, the stereochemically pure isomers of the compounds described herein (i.e., a single enantiomer or a single diastereomer) and mixtures thereof, including their racemic forms, are included within the scope of this invention. For example, when a compound is designated as (R), this means that the compound is substantially free of the (S) isomer. The compounds described herein can be used as racemic mixtures, mixtures enriched with enantiomers or diastereomers, or as single stereoisomers pure in either enantiomer or diastereomer.

[0118] In view of this disclosure, stereochemically pure isomers can be obtained using techniques known in the art. For example, diastereomers can be separated by physical separation methods such as fractional crystallization and chromatography, while enantiomers can be separated by selective crystallization of diastereomer salts with optically active acids or bases or by chiral chromatography. Pure stereoisomers can also be prepared from suitable stereochemically pure starting materials or by using stereoselective reactions.

[0119] The compounds described herein can also have meso compounds. The term "meso compound" refers to a non-optically active stereoisomer. A meso compound contains two or more stereocenters but is not chiral.

[0120] The compounds described herein can also form tautomers. The term "tautomer" refers to a compound that is an interchangeable form of a particular compound structure and has different shifts in hydrogen atoms and electrons. Tautomers are structural isomers of compounds that readily interconvert, typically resulting in the repositioning of protons (hydrogen). Thus, two structures can reach equilibrium through the movement of π electrons and atoms (usually hydrogen). All tautomer forms and mixtures of tautomers of the compounds described herein are included within the scope of this invention.

[0121] The compounds described herein can exist in solvated and non-solventized forms. The term "solvent" refers to the physical association of the compound of the present invention with one or more solvent molecules, for example, through hydrogen bonding. Solvent molecules in a solvate can exist in a regular and / or disordered arrangement. A solvate may contain stoichiometric or non-stoichiometric amounts of solvent molecules. "Solvate" includes both solution-phase and separable solvates. The compounds of the present invention can form solvates with water (i.e., hydrates) or common organic solvents. Exemplary solvates include, but are not limited to, hydrates, ethanolates, methanolates, and isopropanolates.

[0122] As used herein, the name of a compound is intended to cover all possible isomer forms, including stereoisomers of the compound (e.g., enantiomers, diastereomers, racemic mixtures or mixtures thereof and any mixture thereof).

[0123] Example

[0124] The following examples are provided to illustrate the present invention, but should not be construed as limiting the scope of the invention. If specific conditions for experimental methods are not specifically described in the examples, they are generally based on the conventional or recommended conditions provided by the manufacturers of the raw materials and products. Reagents not specifically named are commercially available conventional reagents.

[0125] The structure of each compound was identified by nuclear magnetic resonance (NMR) and / or mass spectrometry (MS). NMR chemical shifts (δ) were determined in 10⁻¹⁰ increments. -6 (ppm) values ​​are given. NMR was determined using a Varian Mercury 300MHz and a Bruker Avance III 400MHz instrument. The solvents used were deuterated dimethyl sulfoxide (DMSO-d6), deuterated chloroform (CDCl3), and deuterated methanol (CD3OD).

[0126] High-performance liquid chromatography (HPLC) was performed on an Agilent 1200DAD HPLC system (Sunfire C18 150×4.6 mm column) and a Waters 2695-2996 HPLC system (Gimini C18 150×4.6 mm column). Liquid chromatography-mass spectrometry (LC-MS) was performed on an Agilent 1200 HPLC-MS / MS system (Sunfire C18 4.6*50 mm 3.5 μm column) and an Agilent 19091S-433 HP-5 HPLC-MS / MS system (XBridge C18 4.6*50 mm 3.5 μm column).

[0127] Chiral high-performance liquid chromatography (HPLC) was performed on an SFC Thar 80, 150, and 200 (waters) system.

[0128] The mean ATPase inhibition rate and IC50 were determined using a Victor Nivo multimode microplate reader (PerkinElmer, USA). 50 value.

[0129] The thin-layer chromatography (TLC) uses Yantai Xinnuo silica gel plates. The plate size used in TLC is 0.15 mm to 0.2 mm, while the plate size used in TLC for product purification is 0.4 mm to 0.5 mm.

[0130] Column chromatography typically uses Qingdao Haiyang 200 to 300 mesh silica gel as a carrier.

[0131] The known raw materials of this invention can be prepared by conventional synthetic methods in the prior art, or can be purchased from ABCRGmbH&Co.KG, Acros Organics, Aldrich Chemical Company, Accela ChemBio Inc, or Darichemical Company, etc.

[0132] Unless otherwise stated in the examples, the following reactions are carried out under an argon or nitrogen atmosphere.

[0133] The terms "argon atmosphere" or "nitrogen atmosphere" refer to a reaction flask equipped with a balloon containing 1L of argon or nitrogen.

[0134] The term "hydrogen atmosphere" refers to a reaction flask equipped with a balloon containing 1L of hydrogen.

[0135] MS stands for mass spectrometry, where (+) indicates a positive mode that typically provides absorption at M+1 (or M+H), where M = molecular weight.

[0136] General Procedure A

[0137]

[0138] Methyl carbamimidothioate sulfuric acidsalt is condensed with methyl chloroformate. The resulting carbamate is then cycloaddition-reacted with a commercially available aryl isocyanate to obtain a six-membered triazine dione core structure, which is then coupled with a commercially available or custom-made primary amine and nucleophilic addition under heating conditions to obtain triazine dione analogs.

[0139] General Procedure B

[0140]

[0141] Benzyl bromide is condensed with thiourea to obtain a bromide salt, which is then condensed with carbonyl diimidazole to obtain a carbonyl monoimidazole. This is subsequently condensed with a commercially available or custom-made amine to obtain a urea, which is then cyclized under the catalysis of carbonyl diimidazole to obtain a six-membered core structure. The six-membered core structure is then nucleophilically substituted with a commercially available or custom-made primary amine under heating conditions to obtain a triazine dione analog.

[0142] General procedure C

[0143]

[0144] The N-boc-protected heterocycle or the N-Boc-substituted carbide ring is deprotected under typical acidic conditions (e.g., TFA or HCl). The resulting amine is then tested in a bioassay or further functionalized via acylation or sulfonation to obtain amides, carbamates, ureas, or sulfonamides.

[0145] General Procedure D

[0146]

[0147] TBS-protected alcohols are exposed to typical conditions (e.g., TBAF or HF-pyridine) to obtain free alcohols.

[0148] General Procedure E

[0149]

[0150] Aryl bromides are coupled with commercially available aryl, vinyl, or alkyl borate esters under typical Suzuki coupling conditions to obtain carbon-linked analogs.

[0151] General Procedure F

[0152]

[0153] Aryl bromides are coupled with commercially available amines under typical Suzuki coupling conditions to obtain nitrogen-linked analogs.

[0154] General procedure G

[0155]

[0156] Alkenes are reduced under typical hydrogenation conditions to obtain saturated heterocyclic or carbocyclic rings.

[0157] Example

[0158] The following examples are provided to illustrate, but are not limited to, the compositions, uses, and methods described herein. The compounds were prepared using the general methods described above.

[0159] The following abbreviations are used throughout the examples: TEA (trimethylamine), DCM (dichloromethane), DMF (N,N-dimethylformamide), DIEA (diisopropylethylamine), MeOH (methanol), PE (petroleum ether), and EA (ethyl acetate).

[0160] Example 1

[0161] Step 1. Synthesis of intermediate 1-1

[0162]

[0163] At 0 °C, a solution of KOH (11.38 g, 202.8 mmol) in water (40 mL) was added dropwise to a mixture of 1-methyl-2-thiopseudourea sulfate (13.9 g, 73.8 mmol) and methyl chloroformate (9.4 g, 99.4 mmol) in water (200 mL). The reaction mixture was stirred at room temperature for 3 hours and then extracted with DCM. The organic extract was dried, and the solvent was evaporated on a rotary evaporator to give intermediate 1-1 (9 g, 82.4%) as a white solid.

[0164] ESI-MS (EI + ,m / z):149.10.

[0165] 1 ¹H NMR (400MHz, chloroform-d): δ 3.73 (s, 3H), 2.46 (s, 3H).

[0166] Step 2. Synthesis of intermediates 1-2

[0167]

[0168] Intermediate 1-1 (1.0 g, 6.75 mmol) was dissolved in DCM (10 mL). Phenyl isocyanate (804 mg, 6.75 mmol) was added to the solution over 5 minutes, and the mixture was stirred at room temperature for 2.5 hours. Then, a freshly prepared solution of sodium (155 mg, 6.75 mmol) in MeOH (1.3 mL) was added over 5 minutes, and the resulting mixture was stirred at room temperature for 16 hours. The mixture was concentrated, and the residue was dissolved in water. The aqueous solution was extracted with ethyl acetate (20 mL x 2) to remove neutral byproducts, and then acidified to pH 1 with concentrated HCl. The precipitated solid was separated by filtration, washed with water, and dried to obtain intermediate 1-2 (660 mg, 41.7%) as a white solid.

[0169] ESI-MS (EI+ ,m / z):236.10

[0170] 1 ¹H NMR (400MHz, methanol-d⁴): δ 7.52–7.39 (m, 3H), 7.32–7.26 (m, 2H), 2.61 (s, 3H).

[0171] Step 3. Synthesis of Example 1

[0172]

[0173] (S)-1-cyclohexylethane-1-amine (106 mg, 0.84 mmol) and HOAc (1.0 mL) were placed in a microwave-safe vial. The resulting mixture was stirred at room temperature for 0.5 hours. Then, intermediate 1-2 (100 mg, 0.42 mmol) was added, the vial was sealed, and the resulting mixture was heated to 145 °C for 4 hours. The mixture was cooled to room temperature, water was added, and the mixture was stirred at room temperature for 15 minutes. The mixture was filtered, the filter cake was washed with water and dried to obtain the title compound (85 mg, 64.3%) as a white solid.

[0174] ESI-MS (EI + ,m / z):315.25.

[0175] 1 H NMR(400MHz,DMSO-d6)δ7.47–7.30(m,3H),7.22(dd,J=7.2,1.8Hz,2H),6.82(br,1H),3.79-3.86(m,1 H),1.78–1.59(m,5H),1.47–1.34(m,1H),1.27–1.12(m,3H),1.10(d,J=6.7Hz,3H),1.04–0.91(m,2H).

[0176] Example 2

[0177] Step 1. Synthesis of intermediate 2-1

[0178]

[0179] Thiourea (6.0 g, 78.9 mmol, 1.3 eq.) was added to a solution of (bromomethyl)benzene (10.0 g, 58.8 mmol) in CH3CN (100 mL). The resulting mixture was stirred at room temperature for 3 hours. The reaction solution was filtered, washed with CH3CN (50 mL), and the filter cake was dried under vacuum to give intermediate 2-1 (13.0 g, 90.2%) as a white solid.

[0180] 1 H NMR (400MHz, DMSO-d6) δ9.06 (s, 4H), 7.45–7.30 (m, 5H), 4.48 (s, 2H).

[0181] Step 2. Synthesis of intermediate 2-2

[0182]

[0183] CDI (8.8 g, 54.2 mmol, 1.3 eq.) and Et3N (5.4 g, 54.2 mmol, 1.3 eq.) were added to a solution of intermediate 2-1 (10.0 g, 40.6 mmol) in THF (100 mL). The resulting mixture was stirred at room temperature under N2 for 2 hours until TLC showed that the reaction was complete. The reaction solution was filtered, and the filtrate was concentrated under vacuum. The residue was purified by silica gel column chromatography (DCM:MeOH = 30:1) to give intermediate 2-2 (7.0 g, 67.3%) as a white solid.

[0184] ESI-MS (EI + ,m / z):261.15.

[0185] 1 H NMR (400MHz, DMSO-d6) δ9.36(d,J=59.7Hz,2H),8.33–8.25(m,1H),7.61(t,J=1.3Hz,1H),7.44–7.24(m,5H),7.01–6.95(m,1H),4.43(s,2H).

[0186] Step 3. Synthesis of intermediates 2-3

[0187]

[0188] Tetrahydro-2H-pyran-4-amine (1.75 g, 17.3 mmol, 1.5 eq.) and Et3N (2.3 g, 23.0 mmol, 2.0 eq.) were added to a solution of intermediate 2-2 (3.0 g, 11.5 mmol) in DMF (10 mL). The resulting mixture was stirred at 80 °C under N2 for 1 hour until TLC and LCMS showed complete reaction. The reaction solution was diluted with water and extracted twice with EtOAc. The organic matter was washed with water and brine, dried over Na2SO4, filtered, and concentrated under vacuum. The reaction mixture was purified by silica gel column chromatography (DCM:MeOH = 30:1) to give intermediate 2-3 (1.5 g, 44.6%) as a yellow solid.

[0189] ESI-MS (EI + ,m / z):294.20.

[0190] 1 H NMR (400MHz, DMSO-d6) δ8.49(s,2H),7.41–7.34(m,2H),7.30(t,J=7.4Hz,2H),7.23(dd,J=8.3,6.1Hz,1H),7.07(d,J=8.0Hz,1H),4.28(s,2H),3. 87–3.76(m,2H),3.60(ddt,J=15.0,7.7,4.4Hz,1H),3.35(d,J=1.7Hz,1H ),3.29(d,J=1.8Hz,1H),1.73–1.62(m,2H),1.45(qd,J=12.1,4.4Hz,2H).

[0191] Step 4. Synthesis of intermediates 2-4

[0192]

[0193] CDI (4.8 g, 29.6 mmol, 2.0 eq.) and DIEA (3.9 g, 30.2 mmol, 2.0 eq.) were added to a solution of intermediate 2-3 (4.5 g, 15.3 mmol) in DMF (15 mL). The resulting mixture was stirred at 110 °C for 3 hours until TLC and LCMS showed that the reaction was complete. The reaction mixture was purified by reverse-phase column chromatography to give intermediate 2-4 (1.0 g, 21.2%) as a yellow liquid.

[0194] ESI-MS (EI + ,m / z):320.15.

[0195] 1 H NMR (400MHz, DMSO-d6) δ7.40–7.35(m,2H),7.30(t,J=7.4Hz,2H),7.23(dd,J=8.4,6.1Hz,1H),4.24(s,2H),3.89(d d,J=11.1,4.1Hz,2H),3.64–3.56(m,1H),3.30(t,J=11.2Hz,2H),2.59(qd,J=12.4,4.7Hz,2H),1.40–1.33(m,2H).

[0196] Step 5. Synthesis of Example 2

[0197]

[0198] A solution of intermediate 2-4 (300 mg, 0.94 mmol) in (S)-1-cyclohexylethyl-1-amine (300 mg, 2.36 mmol) was stirred overnight at 90 °C in a sealed tube until LC-MS showed the reaction was complete. The reaction mixture was purified by preparative HPLC to give the title compound (45 mg, 14.9%) as a white solid.

[0199] ESI-MS (EI + ,m / z):323.23.

[0200] 1 H NMR (400MHz, DMSO-d6) δ10.32(s,1H),6.61(d,J=4.8Hz,1H),4.66(t,J=12.1H z,1H),3.89(dd,J=11.2,4.2Hz,2H),3.75(d,J=5.0Hz,1H),3.33(s,1H),3.28 (s,1H),2.53(s,1H),2.45(dd,J=12.6,4.6Hz,1H),1.76–1.56(m,5H),1.42(d ,J=12.5Hz,3H),1.24–1.10(m,3H),1.05(d,J=6.7Hz,3H),0.99–0.86(m,2H).

[0201] Example 3

[0202] Step 1. Synthesis of intermediate 3-1

[0203]

[0204] To a solution of intermediate 2-2 (3.0 g, 11.5 mmol) in DMF (10 mL), propan-2-amine (1.0 g, 17.3 mmol, 1.5 eq.) and Et3N (2.3 g, 23.0 mmol, 2.0 eq.) were added. The resulting mixture was stirred at 80 °C under N2 for 1 hour until TLC and LCMS showed complete reaction. The reaction solution was diluted with water and extracted twice with EtOAc. The organic layer was washed with water and brine, dried over Na2SO4, filtered, and concentrated under vacuum. The residue was purified by silica gel column chromatography (DCM:MeOH = 30:1) to give intermediate 3-1 (800.0 mg, 28.5%) as a yellow solid. ESI-MS (EI) + ,m / z):252.15.

[0205] 1¹H NMR (400MHz, chloroform-d) δ 7.33–7.17 (m, 5H), 4.20 (s, 2H), 3.86 (dq, J = 14.0, 6.6Hz, 1H), 1.13 (d, J = 6.5Hz, 6H)

[0206] Step 2. Synthesis of intermediate 3-2

[0207]

[0208] CDI (1.1 g, 6.4 mmol, 2.0 eq.) and DIEA (823.0 g, 6.4 mmol, 2.0 eq.) were added to a solution of intermediate 3-1 (800.0 mg, 3.2 mmol) in DMF (5 mL). The resulting mixture was stirred at 110 °C for 3 hours until TLC and LCMS showed that the reaction was complete. The reaction mixture was purified by reverse-phase column chromatography to give intermediate 3-2 (200.0 mg, 24.3%) as a yellow liquid.

[0209] ESI-MS (EI + ,m / z):278.20.

[0210] 1 H NMR (400MHz, DMSO-d6) δ7.42–7.35(m,2H),7.35–7.28(m,2H),7.28–7.21(m,2H),4.86(p,J=6.9Hz,1H),4.28(s,2H),1.32(d,J=6.9Hz,6H).

[0211] Step 3. Synthesis of Example 3

[0212]

[0213] A solution of intermediate 3-2 (150 mg, 0.541 mmol) in (S)-1-phenylethyl-1-amine (656 mg, 5.409 mmol) was stirred overnight at 100 °C in a sealed tube until LC-MS showed the reaction was complete. The reaction mixture was purified by reverse-phase column chromatography (~40% MeCN, 0.1% formate) to give the title compound (5.8 mg, 3.9%) as a white solid.

[0214] ESI-MS (EI + ,m / z):275.25.

[0215] 1H NMR(400MHz, DMSO-d6)δ10.46(s,1H),7.35(d,J=4.8Hz,4H),7.28–7.24(m,1H),5.04(p ,J=7.0Hz,1H),4.80(hept,J=6.8Hz,1H),1.42(d,J=6.9Hz,3H),1.30(d,J=6.9Hz,6H).

[0216] Example 4

[0217]

[0218] 6-(benzylthio)-3-(tetrahydro-2H-pyran-4-yl)-1,3,5-triazine-2,4(1H,3H)-dione (200 mg, 0.063 mmol) and (S)-1-(m-tolyl)ethyl-1-amine (127 mg, 0.094 mmol) in dioxane (5.0 mL) were loaded into a 20.0 mL microwave tube and heated to 110 °C. The resulting solution was concentrated to dryness under vacuum. The crude product was purified by preparative HPLC to obtain the title compound (101.4 mg, yield: 49.0%).

[0219] MS: m / z = 331.1(M+1, ESI) + ).

[0220] 1 H NMR (400MHz, MeOD) δ7.15 (ddd, J=34.6, 21.0, 7.6Hz, 4H), 5.10 (q, J=6.8Hz, 1H), 4.80 (tt, J=12.2, 4.0Hz, 1H) ,3.99(dd,J=11.4,3.8Hz,2H),3.44(t,J=11.7Hz,2H),2.66(qd,J=12.4,4.8Hz,2H),1.51(t,J=11.8Hz,5H).

[0221] Example 5

[0222]

[0223] Pd(dppf)Cl2 (18 mg, 0.25 mmol) and Cs2CO3 (165 mg, 0.5 mmol) were added to a solution of (S)-6-((1-(3-bromophenyl)ethyl)amino)-3-(tetrahydro-2H-pyran-4-yl)-1,33,5-triazine-2,4(1H,3H)-dione (100 mg, 0.25 mmol) (prepared in a similar manner from (S)-1-(3-bromophenyl)ethyl-1-amine according to the synthesis method of Example 4) and 1,3-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxoborhexacyclopentan-2-yl)-1H-pyrazole (83 mg, 0.375 mmol) in 1,4-dioxane (5.00 mL) and H2O (0.5 mL). The mixture was stirred at 110 °C for 16 hours under N2. The solvent was removed under vacuum. The residue was diluted with water (10 mL) and extracted with DCM (10 mL x 3). The combined organic layers were dried over Na2SO4, filtered, and concentrated. The residue was purified by preparative HPLC to give the title compound as a white solid (35.7 mg, 34% yield).

[0224] MS: m / z = 411.1(M+1, ESI) + ).

[0225] 1 H NMR(500MHz, DMSO)δ7.86(s,1H),7.36(dd,J=13.3,5.5Hz,2H),7.29(d,J=7.8Hz,1H),7.20(d,J=7.6Hz,1H),5.14–5.00(m,1H),4.72–4.59(m,1 H),3.87(d,J=11.1Hz,2H),3.77(s,3H),3.28(d,J=11.9Hz,2H),2.49–2.42(m,2H),2.27(s,3H),1.45(d,J=6.9Hz,3H),1.39(d,J=10.6Hz,2H).

[0226] Example 6

[0227]

[0228] To a solution of (S)-6-((1-(3-bromophenyl)ethyl)amino)-3-(tetrahydro-2H-pyran-4-yl)-1,3,5-triazine-2,4(1H,3H)-dione (100 mg, 0.3 mmol) (prepared in a similar manner from (S)-1-(3-bromophenyl)ethyl-1-amine according to the synthetic method of Example 4) and SM1 (42 mg, 0.5 mmol) in DMSO (5.00 mL), CuI (72 mg, 0.4 mmol), L-proline (43 mg, 0.4 mmol), and Cs₂CO₃ (248 mg, 0.8 mmol) were added. The mixture was stirred at 130 °C for 16 hours under N₂. The mixture was filtered and purified by preparative HPLC to give the title compound as a white solid (12.4 mg, 12% yield).

[0229] MS: m / z = 397.1 (M+1, ESI) + ).

[0230] 1H NMR (400MHz, MeOD) δ8.10(s,1H),7.72(s,1H),7.57(d,J=8.0Hz,1H),7.45(t,J=7.9Hz,1H),7.31(d,J=7.6Hz,1H),6.32(s,1H),5.23(d,J=6.8Hz ,1H),4.78(t,J=12.0Hz,1H),3.99(dd,J=11.6,3.8Hz,2H),3.44(t,J=11 .9Hz,2H),2.74–2.55(m,2H),2.33(s,3H),1.55(dd,J=18.3,9.5Hz,5H).

[0231] Example 7

[0232]

[0233] 3-((1r,3S)-3-((tert-butyldimethylsilyl)oxy)cyclobutyl)-6-(((S)-1-cyclohexylethyl)amino)-1,3,5-triazine-2,4(1H,3H)-dione (110 mg, 0.26 mmol) (prepared in a similar manner from (1r,3r)-3-((tert-butyldimethylsilyl)oxy)cyclobut-1-amine and (S)-1-cyclohexylethyl-1-amine according to the synthetic methods of Examples 2 and 4) was stirred in a solution of HCl / dioxane (2 mL, 1.0 N, 2.0 mmol) at room temperature for 3 hours. The solution was purified by preparative HPLC to give the title compound (5.0 mg, 6% yield) as a white solid.

[0234] MS:m / z=309(M+H,ESI+ ).

[0235] 1 H NMR (400MHz, CD3OD) δ5.50–5.39(m,1H),4.54(s,1H),3.92–3.84(m,1H),3.06(ddd,J=15.0,10.5,7.6Hz,2H),2.23(ddd ,J=13.5,7.3,1.9Hz,2H),1.87–1.60(m,6H),1.41(s,1H),1.31–1.18(m,3H),1.14(d,J=6.7Hz,3H),1.10–0.89(m,3H).

[0236] Example 8

[0237]

[0238] Step 1. Synthesis of intermediate 8-1

[0239] Pd(pph3)4 (175 mg, 0.2 mmol) was added to a solution of (S)-6-((1-(3-bromophenyl)ethyl)amino)-3-(tetrahydro-2H-pyran-4-yl)-1,3,5-triazine-2,4(1H,3H)-dione (300 mg, 0.8 mmol) (prepared in a similar manner from (S)-1-(3-bromophenyl)ethyl-1-amine according to the synthesis method of Example 4) and tributyl(1-ethoxyvinyl)stanane (551 mg, 1.5 mmol) in 1,4-dioxane (20.00 mL). The resulting mixture was stirred at 80 °C for 16 hours. The mixture was filtered and concentrated. The residue was dissolved in 1N HCl (1 mL) and THF (3 mL) and stirred at room temperature for 1 hour. The mixture was concentrated and purified by rapid chromatography (SiO2, 10 / 1DCM / MeOH) to obtain intermediate 8-1 (110 mg, 42% yield) as a yellow oil.

[0240] MS: m / z = 359.1 (M+1, ESI) + ).

[0241] Step 2. Synthesis of Example 8

[0242]

[0243] A solution of intermediate 8-1 (100 mg, 0.3 mmol) in THF (3.00 mL) was stirred at 0 °C, and MgBrMe (1.1 mL) was added. The mixture was stirred at 0 °C for 3 hours. The mixture was quenched with H2O (1 mL) and concentrated. The residue was purified by preparative HPLC to give the title compound as a white solid (12.4 mg, 12% yield).

[0244] MS: m / z = 357.2(M+1, ESI) + ).

[0245] 1 H NMR (400MHz, MeOD) δ7.50(d,J=8.3Hz,1H),7.38(d,J=7.8Hz,1H),7.30(t,J=7.7Hz,1H),7.22(d,J=7.6Hz,1H),5.15(q,J=6.9Hz,1H),4. 79(ddd,J=16.0,8.1,3.9Hz,1H), 4.00(dd,J=11.3,4.1Hz,2H), 3.44(t,J=11.8Hz,2H), 2.63(dt,J=12.6,5.5Hz,2H), 1.59–1.44(m,11H).

[0246] Example 9

[0247] Step 1. Synthesis of intermediate 9-1

[0248]

[0249] Pd(dppf)Cl2 (1.1 g, 1.5 mmol) and K2CO3 (3.1 g, 22.6 mmol) were added to a solution of (S)-1-(3-bromophenyl)ethyl-1-amine (1.5 g, 7.5 mmol) and potassium vinyltrifluoroborate (2.0 g, 15.1 mmol) in 1,4-dioxane (20.00 mL) and H2O (2 mL). The mixture was stirred at 110 °C for 2.0 h under N2. The residue was diluted with water (20 mL) and extracted with DCM (20 mL x 3). The organic layers were combined, dried over Na2SO4, filtered, and concentrated. The residue was purified by rapid chromatography (SiO2, 10 / 1 DCM / MeOH) to give intermediate 9-1 (830 mg, 75% yield) as a yellow oil. MS: m / z = 148.1 (M+1, ESI) + ).

[0250] Step 2. Synthesis of intermediate 9-2

[0251]

[0252] A solution of intermediate 9-1 (800 mg, 7.5 mmol) and intermediate 2-4 (1.4 g, 15.1 mmol) in 1,4-dioxane (20.00 mL) was stirred at 110 °C for 16.0 h. The residue was concentrated under vacuum and purified by rapid chromatography (SiO2, 1 / 1 PE / EA) to give intermediate 9-2 (1.2 g, 69% yield) as a yellow oil.

[0253] MS: m / z = 148.1(M+1, ESI) + ).

[0254] Step 3. Synthesis of intermediate 9-3

[0255]

[0256] To a solution of intermediate 9-2 (1.1 g, 3.2 mmol) and 2,6-dimethylpyridine (344 mg, 3.2 mmol) in THF (20.00 mL) and H₂O (4.00 mL), NaIO₄ (2.75 g, 12.8 mmol) and K₂O·2H₂O (118 mg, 0.3 mmol) were added, and the resulting mixture was stirred at 25 °C for 4.0 h. The mixture was filtered and concentrated. The residue was purified by rapid chromatography (SiO₂, 10 / 1 DCM / MeOH) to give intermediate 9-3 (600 mg, 55% yield) as a yellow oil.

[0257] MS: m / z = 148.1(M+1, ESI) + ).

[0258] Step 4. Synthesis of Example 9

[0259]

[0260] A mixture of intermediate 9-3 (80 mg, 0.2 mmol) in THF (3.00 mL) was stirred at 0 °C, and isopropyl magnesium bromide (0.9 mL) was added. The mixture was stirred at 0 °C for 3.0 h. The mixture was quenched with H2O (1 mL) and concentrated. The residue was purified by preparative HPLC to give the title compound as a white solid (18.3 mg, 22% yield).

[0261] MS: m / z = 389.2(M+1, ESI) + ).

[0262] 1H NMR (400MHz, MeOD) δ7.39–7.10 (m, 4H), 5.15 (q, J=6.9Hz, 1H), 4.79 (ddd, J=12. 1,8.2,4.2Hz,1H),4.29(dd,J=6.9,2.7Hz,1H),4.00(dd,J=11.4,4.3Hz,2H),3 .44(t,J=11.7Hz,2H),2.65(qd,J=12.3,4.6Hz,2H),1.90(dq,J=13.6,6.9Hz,1 H),1.67–1.36(m,5H),0.96(dd,J=6.7,3.9Hz,3H),0.76(dd,J=6.8,1.4Hz,3H).

[0263] Example 10

[0264]

[0265] Example 10 was prepared from (S)-1-(2,4-difluorophenyl)ethyl-1-amine in the same manner as in Example 4.

[0266] MS: m / z = 353.4(M+1, ESI) + ).

[0267] 1 HNMR(500MHz,MeOD)δ7.51–7.32(m,1H),6.95(ddt,J=13.8,8.4,2.6Hz,2H),5.33(q,J=7.0Hz,1H),4.79(tt,J=1 2.2,4.0Hz,1H),3.99(dd,J=11.6,3.8Hz,2H),3.44(t,J=12.0Hz,2H),2.74–2.57(m,2H),1.52(t,J=5.8Hz,5H).

[0268] Similarly, the compounds in the table below (Table 1) were prepared according to the procedure described above.

[0269] Table 1

[0270]

[0271]

[0272]

[0273]

[0274]

[0275]

[0276]

[0277]

[0278]

[0279]

[0280]

[0281]

[0282]

[0283]

[0284]

[0285]

[0286]

[0287]

[0288]

[0289]

[0290]

[0291]

[0292]

[0293]

[0294]

[0295]

[0296]

[0297]

[0298]

[0299]

[0300]

[0301]

[0302]

[0303]

[0304]

[0305]

[0306]

[0307]

[0308]

[0309]

[0310]

[0311]

[0312]

[0313]

[0314]

[0315] Biological testing

[0316] Experiment 1 Myosin Inhibitory Efficacy

[0317] For the testing context, the biochemical assay combines the ATPase activity of bovine cardiac myosin with an enzyme-coupled system consisting of pyruvate kinase and lactate dehydrogenase (PK / LDH). The decrease in absorbance of NADH (at 340 nm) over time is monitored to measure the inhibitory activity of small molecule drugs. In this assay, PK converts ADP (adenosine diphosphate) to ATP (adenosine triphosphate) by converting PEP (phosphoenolpyruvate) to pyruvate. Then, LDH converts pyruvate to lactate by converting NADH (nicotinamide adenine dinucleotide) to NAD (oxidized nicotinamide adenine dinucleotide).

[0318] In our experiments, bovine myofibrils, sloughed and isolated from frozen bovine left ventricles, were used as the source of myosin in ATPase assays. Based on the literature (DOI:10.1074 / jbc.M117.776815), a myofibril system with 50% pCa was selected. 50The activated calcium concentration (or pCa = 6.25) was used as the final condition for assessing activation activity. Myofibrillar ATPase activity was measured in a buffer solution (PM12 buffer) at pH 6.8 containing 12 mM PIPES (piperazine-N,N'-bis(2-ethanesulfonic acid)) and 2 mM magnesium chloride. The final assay conditions were 1 mg / mL bovine cardiac myofibrillar fibers, 1:20 stock PK / LDH (Sigma-Aldrich, catalog number P0294-5X5ML), 50 uM ATP, 1 mM DTT (dithiothreitol), 0.75 mM NADH, 1.5 mM PEP, and pCa = 6.25. 50 (pCa = 6.25). The compound was dissolved in DMSO (dimethyl sulfoxide). Serial dilutions of the compound were created to achieve the final desired compound concentration in 150 μL volumes at a fixed DMSO concentration of 2% (v / v). 75 μL of a solution containing bovine cardiac myofibrils, PK / LDH, and calcium was added to a 96-well plate to obtain a 7-point dose-response. In some cases, a 10-point reaction was used to repeat the ATPase assay for the compound of interest. The compound was added to the myofibril solution and incubated for 5 min. The enzymatic reaction was initiated by adding 75 μL of a solution containing ATP, PEP, NADH, the compound, and calcium. ATPase activity was measured using a clear-bottom plate by reading the absorbance at 340 nm in kinetic mode at 25 °C for 15 min using a PerkinElmer Victor Nivo plate reader. The slope of the absorbance change over time in the first 10 min was normalized to the slope of the control wells containing all reagents (including DMSO) but not the compound. Then, in GraphPad Prism 9, the normalization rate was plotted as a function of the small molecule concentration. The data was fitted to a four-parameter fit, and the IC was calculated using GraphPad Prism 9. 50 Any agent that fails to achieve 50% inhibition at the highest tested concentration is reported as having an IC50 greater than the highest tested concentration. 50 (i.e. IC) 50 >200uM).

[0319] Table 2. Myosin inhibitory activity

[0320]

[0321]

[0322]

[0323]

[0324] Experiment 2. Comparison of the inhibitory efficacy of myosin in cardiac and skeletal myofibrils

[0325] Bovine myofibrils (skinless) were isolated from frozen bovine left ventricles, and rabbit skeletal myofibrils (skinless) were isolated from frozen rabbit psoas major and minor muscles as sources of myosin for ATPase assays. Following the literature (DOI:10.1074 / jbc.M117.776815), the calcium concentration required to achieve 50% activation of the myofibril system (pCa = 6.25 for bovine myofibrils and pCa = 6 for rabbit skeletal myofibrils) was selected as the final condition for evaluating activation activity. The remaining ATPase assay conditions were the same as described in Experiment 1.

[0326] Table 3. Comparison of myosin inhibitory activity in cardiac and skeletal myofibrils

[0327]

[0328]

[0329] The compounds of this invention exhibit great potency against cardiac myofibrils. Furthermore, Example 10 shows significantly less potency in inhibiting rapid skeletal myofibril activity. Data confirm that Example 10 has better cardiac-skeletal myosin selectivity, thus potentially leading to better safety.

[0330] Experiment 3. Measurement of cardiomyocyte contractility

[0331] The effects of the compound on sarcomere shortening in isolated rat ventricular myocytes were evaluated using an IonOptix instrument.

[0332] Myocytes were placed in a chamber mounted on an inverted microscope stage and continuously perfused with an oxygenated Tyrode solution containing (in millimoles): 121 NaCl, 5 KCl, 2.8 NaCH3CO2, MgCl2·6H2O, glucose, NaHCO3, Na2HPO4·7H2O, and 1.5 mM CaCl2. The solution was preheated to 36 ± 1 °C and electrically stimulated with a 4 ms square-wave bipolar pulse (10 V) at 1 Hz via two platinum electrodes connected to a Myopacer field stimulator (IonOptix Corporation). Cells were illuminated by microscope light. Cell images were acquired using an x40 UV epifluorescence objective and transferred to the microscope side port, where the cell images were recorded by a charge-coupled device (CCD) camera (MyoCam, IonOptix Corporation), converting optical brightness (pixels) into electrical signals (voltages). The MyoCam configuration was capable of acquiring up to 240 images per second (240 Hz frame rate). The contractile properties of myocytes were analyzed in real time using a video detector and a personal computer-based data acquisition system (Ionwizard 6.0, IonOptix Corporation). Only myocytes with clearly defined striations and a resting sarcomere length greater than or equal to 1.75 μm before pacing were used, as this was considered to represent the lower limit of healthy cells.

[0333] Sarcoid shortening was monitored in a control solution (prodrug) until a stable recording (baseline period) was obtained. To determine the response to the compound, myocytes were first perfused with Tyrode buffer for 60 seconds, followed by perfusion with the compound for at least 5 minutes (or until a steady state was reached, up to a maximum of 10 minutes). Each cell received two concentrations of the test compound (5 and 15 μM or 5 and 10 μM). For some cells, a washout period was performed after the last concentration. The duration of the washout period was variable, resulting in variability in the washout data. In individual cells, a single concentration of isoproterenol (100 nM) was applied. Data were recorded continuously using IonOptix software. Contractility data were analyzed using Ionwizard software (IonOptix). For each cell, 10–15 contractile transients were averaged and compared between baseline and post-treatment.

[0334] Table 4. Effects of compounds on fractional shortening of muscle cells

[0335]

[0336]

[0337] * refers to %FS at 10uM, and others refer to %FS at 15uM.

[0338] The fractional shortening ratio at 5 μM / 10 or 15 μM indicates the responsiveness of muscle cell contractility to compound treatment. A lower ratio suggests that the compounds of the present invention may have a higher in vivo therapeutic window.

[0339] Experiment 4. Pharmacokinetic Characteristics

[0340] The pharmacokinetic characteristics of the compound were determined by intravenous (IV) administration (1 mg / kg) and oral (PO) administration (5 mg / kg) in male SD rats. The compound was administered with its free base in a 5% DMAC + 25% PEG-400 + 70% (30% 2-HP-β-CD aqueous solution). The compound was administered intravenously at 1 mg / kg and orally at 5 mg / kg. For the IV group, blood samples were collected at 0, 0.083, 0.25, 0.5, 1, 2, 4, 8, and 24 hours post-administration, with continuous blood collection to obtain plasma. For the PO group, blood samples were collected at 0, 0.25, 0.5, 1, 2, 4, 6, 8, and 24 hours post-administration, with continuous blood collection. Approximately 150 μL of whole blood per time point was collected via the jugular vein in K2EDTA tubes. Blood samples were placed on ice and centrifuged at 2000g for 5 minutes, with plasma samples obtained within 15 minutes. The PK parameters were estimated using a non-compartmental model based on WinNonlin 8.2.

[0341] Table 5. Pharmacokinetic parameters of the examples in male SD rats

[0342]

[0343] The compounds of this invention typically exhibit a shorter half-life. This can be an advantage because a shorter half-life reduces the time required to reach steady-state equilibrium. It can also reduce or prevent clinical accumulation of the drug in the body, avoiding the risks associated with accumulation.

[0344] Experiment 5. Echocardiographic assessment of the acute pharmacodynamic effects on myocardial contractility in rats.

[0345] The effects of the compound on cardiac function were determined by echocardiography in Spraw-Dawley rats. Rats were lightly anesthetized with 1–2% isoflurane. The compound was administered orally via tube feeding as a single PO dose. Baseline cardiac function was measured 1 day prior to administration. The effects of the compound on cardiac function were measured at 1, 3, 6, and 24 hours post-administration. Approximately 250 μL of whole blood was obtained via tail vein immediately after echocardiography at approximately 1, 3, 6, and 24 hours post-administration. The blood was placed in plasma separation tubes containing K2 EDTA and stored on moist ice until processing. The blood samples were centrifuged at 2,000 g (4,400 rpm, Eppendorf 5417R) for 10 min at 4 °C. The plasma samples were then transferred to microtubes and stored at -80 °C for subsequent LC / MS analysis. Data were plotted as minor axis shortening reduction vs. plasma compound concentration. The therapeutic window was determined to be IC based on the literature (DOI: https: / / doi.org / 10.1021 / acs.jmedchem.1c01290). 50 / IC 10 .

[0346] Figure 2 Example 10 showed a dose-dependent effect below 10 mpk and did not further inhibit cardiac contractility at 20 mpk. This result indicates that Example 10 has better safety compared to other tested compounds. Data plotted using plasma exposure (PK) vs. fractional shortening (OD, FS% to baseline) also confirmed that Example 10 has a better therapeutic window, with a shallower curve slope.

Claims

1. A compound of formula (II) or a pharmaceutically acceptable salt thereof, in, n is 0, 1, or 2; R1 is selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, and C3-C8 cycloalkyl. R3 is selected from C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C3-C8 cycloalkyl, 4-8 membered heterocyclic groups containing one or more N, O, S and S(O)2, C6-C 12 aryl and 4-8 membered heteroaryl groups comprising one or more N, O, S and S(O)2, wherein C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C3-C8 cycloalkyl, 4-8 membered heterocyclic, C6-C 12 Each of the aryl and 4-8 heteroaryl groups is independently unsubstituted or replaced by one to four selected from R each time it appears. 3 Substituent substitution of the group, wherein R 3 The functional groups include deuterium, halogen, amino, nitro, oxo, cyano, hydroxyl, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 hydroxyalkyl, and -NR. a R b -C(O)R a -C(O)NR a R b -C(O)OR a -OC(O)R a -S(O) m R a and -S(O) m NR a R b composition; R4 and R5 are independently selected from hydrogen, deuterium, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, and C3-C8 cycloalkyl, wherein each of the C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, and C3-C8 cycloalkyl is independently unsubstituted or replaced by one or more of deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, and -NR in each occurrence. c R d -C(O)R c -C(O)NR c R d -C(O)OR c and -OC(O)R c Substituents of the substituents; Alternatively, R4 and R5, together with the C atoms they are bonded to, form C3-C6 cycloalkyl groups, 4-8 membered heterocyclic groups containing 1-2 N and O atoms, or C6-C... 12 aryl and 5-6 heteroaryl groups comprising 1-2 N and O atoms, wherein each of the ring structures is optionally separated by one to four atoms selected from deuterium, halogen, amino, cyano, hydroxyl, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 hydroxyalkyl, -NR c R d -C(O)R c -C(O)NR c R d -C(O)OR c and -OC(O)R c Substituents of the substituents; R a R b R c and R d It is independently selected from hydrogen, deuterium, halogen, amino, cyano, hydroxyl, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl and C1-C6 hydroxyalkyl; Compound (II) is not any of the following compounds: 。 2. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R1 is selected from hydrogen, hydroxyl, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, and C1-C3 hydroxyalkyl.

3. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R1 is H, -OH, –CH3, –CH2CH3, –CH(CH3)2, –CH2OH, -CF3 or .

4. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R3 is selected from C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 hydroxyalkyl, C3-C6 cycloalkyl, phenyl, 5-6 membered heterocyclic groups comprising 1-2 N, O, S and S(O)2 atoms, and 5-6 membered heteroaryl groups comprising 1-2 N, O, S and S(O)2 atoms, and R3 is optionally separated by one or two radicals selected from R... 3 Substituent substitution of the group, wherein R 3 The functional groups include deuterium, halogen, amino, nitro, oxo, cyano, hydroxyl, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 haloalkyl, C1-C3 hydroxyalkyl, and -C(O)R. a -C(O)NR a R b -S(O)2R a and -S(O)2NR a R b composition.

5. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R4 and R5 are independently selected from -CH3 and -CF3; Alternatively, R4 and R5 together with the C atoms they are bonded to form: , , , , , , , , , , , , and Each of the ring structures is optionally substituted by one or two substituents selected from -F, -Cl, -Br, -OH, -CH3, -CH2CH3, -CH(CH3)2, -OCH3, -CF3, -CH2CF3, -C(O)CH3, -C(O)CH(CH3)2, -C(O)OCH3 and -C(O)OC(CH3)3.

6. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R3 is... , , , , , , , , , , , , , or R3 is optionally separated by one or more radicals selected from deuterium, halogen, amino, nitro, oxo, cyano, hydroxyl, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, -NR a R b -C(O)R a -C(O)NR a R b -C(O)OR a -OC(O)R a -S(O) m R a and -S(O) m NR a R b Substituents are substituted.

7. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of formula (III): 。 8. A compound selected from: , Or its pharmaceutically acceptable salt.

9. A pharmaceutical composition comprising a therapeutically effective amount of the compound according to any one of claims 1 to 8 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

10. Use of the compound of any one of claims 1 to 8 or a pharmaceutically acceptable salt thereof or the pharmaceutical composition of claim 9 in the preparation of a medicament for treating hypertrophic cardiomyopathy (HCM) or heart disease having the pathophysiological characteristics of HCM.

11. The use according to claim 10, wherein the HCM is obstructive or non-obstructive, or caused by sarcomere and / or non-sarcomere mutations.

12. Use of the compound of any one of claims 1 to 8 or a pharmaceutically acceptable salt thereof or the pharmaceutical composition of claim 9 in the preparation of a medicament for treating a disease or condition, wherein the disease or condition is selected from heart failure with normal ejection fraction, ischemic heart disease, angina pectoris, and restrictive cardiomyopathy.

Citation Information

Patent Citations

  • Pyrimidinedione compounds against cardiac conditions

    CN105473576A

  • Myosin inhibitor, as well as preparation method and application thereof

    CN110698415A